Clean Power Hydrogen - Proposed Fundraising
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND SHALL NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY NEW ORDINARY SHARES OF CLEAN POWER HYDROGEN PLC IN
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION EU NO. 596/2014, AS RETAINED AND APPLICABLE IN THE

Clean Power Hydrogen plc
("CPH2", the "Company" or the "Group")
Proposed Firm Placing of
Proposed Conditional Placing of
Proposed Directors Subscription of
Proposed Conditional Subscription to raise up to
Proposed Retail Offer targeting a minimum raise of
at a price of
Clean Power Hydrogen plc (AIM: CPH2), the UK-based green hydrogen technology company, today announces that it has conditionally raised approximately
In addition, the Company has conditionally raised a further
Furthermore, the Company recognises the importance of its retail Shareholders and, in particular, the significant contribution of clients of West Hill Capital LLP ("West Hill") to the Company's successful capital raises both pre- and post- the Company's admission to trading on AIM in 2022. West Hill has informed the Company that its clients have indicated an intention to subscribe for up to
Certain Directors, and elected Directors, of the Company have noted their intention to subscribe for 666,667 new Ordinary Shares (the "Directors Subscription Shares") at the Issue Price (the "Directors Subscription").
The Company intends to provide existing Shareholders who have not taken part in the Placing with the opportunity to subscribe for 33,333,333 new Ordinary Shares (the "Retail Offer Shares" and together with the Firm Placing Shares, Conditional Placing Shares, Subscription Shares and Directors Subscription Shares, the "New Ordinary Shares") and targeting a minimum raise of
Under the components of the Fundraising outlined above, the Company will issue up to 500,666,666 New Ordinary Shares at the Issue Price to raise up to
The Firm Placing is conditional on, among other things, admission of the Firm Placing Shares to trading on AIM, which is expected to be on or around
The Firm Placing is not conditional upon the Conditional Placing, the Retail Offer, Directors Subscription or the Conditional Subscription. For the avoidance of doubt, the Retail Offer is not part of the Placing, Directors Subscription or the Subscription.
Cavendish Capital Markets Limited is acting as nominated adviser in connection with the Fundraising and TPI is acting as placing agent in connection with the Placing and as retail offer coordinator in connection with the Retail Offer.
Background to and Reasons for the Placing
Introduction
CPH2 is the developer of market disrupting and IP-protected Membrane-Free Electrolyser ("MFE") technology for the co-production of high purity hydrogen and above medical-grade purity oxygen. CPH2 has developed a brand-new category of electrolysis technology. Unlike legacy approaches to electrolysis such as Alkaline Water Electrolysis and Proton Exchange Membrane electrolysers, CPH2's technology avoids fragile, unreliable and expensive membranes, platinum group metals and PFAS "forever chemicals" (banned in several countries), while operating efficiently with variable and intermittent renewable power from wind and solar.
Market
Under its new capital light model, CPH2 will target organisations making use of, or developing projects that require, Membrane free electrolysis, mixed gas handling technology or any of the subsystem processes used in MFE, as applicable to Alkaline or PEM electrolysis. The Company has identified over 100 major organisations which can be profitably addressed globally, representing thousands of projects. Previous supplier relationships and competitors have now become target clients. Electrolysers Market Report 2025-2031 from MaketsandMarket™ valued this space at over
Technology
The Company's MFE system is modular, fully automated and designed for low operating and maintenance costs. A patented cryogenic heat‑exchange process enables production of advanced industry‑grade hydrogen and medical grade oxygen, with very low stack degradation and high reliability. CPH2's MFE110 demonstrator unit has successfully completed Factory Acceptance Tests ("FAT") and Site Acceptance Tests at Northern Ireland Water's wastewater treatment site in Belfast. The MFE110 has demonstrated independently verified higher-value hydrogen purity of 99.999mol%, exceeding fuel cell grade purity requirements, and oxygen of 99.7%, exceeding medical grade purity requirements and marking a clear contrast with traditional electrolysers which are required to vent their lower purity oxygen.
The Company's 1MW unit, the MFE220 ("MFE220"), is based on the technology previously deployed with Northern Ireland Water with the MFE110. The MFE220 electrolyser has successfully completed FAT1 and FAT2. As announced on the
As announced
Strategy
Strategically, CPH2 aims to deliver licensable technology that can deliver the lowest levelised cost of hydrogen ("LCOH") in this sector of the market. Previously, the Company's business model involved a two-fold manufacturing and licensing strategy. Going forward, with respect to the Board's decision to not progress with manufacturing activities, CPH2 is adopting a capital-light business model focused on its proven ability to licence fully secured intellectual property, derived from its ongoing and advanced research and development capability. The Company has now been granted 16 patents across 12 jurisdictions, including USA, Japan, India and across the middle east. There are a further 17 patents pending.
The Company expects to progress a strategy centred on the efficient commercialisation and further global licensing of its intellectual property, with additional strategic and manufacturing partnerships being actively evaluated. CPH2 is expected to licence upgraded designs for the successfully FAT3 tested MFE110 electrolyser including upgraded designs for the successfully FAT2 tested larger scale MFE220 technology and pursuing FAT3 with larger manufacturing partners. Discussions have been held with a number of interested manufacturing parties and early progress has been made with CPH2 signing a binding Term Sheet with Hidrigin, relating to Hidrigin subscribing for a secured
Current licensing partners include BENTEC Solutions (formerly Kenera Energy Solutions; Middle East and parts of Europe), Fabrum (Australia and New Zealand) and Hidrigin (Ireland). A non-binding agreement with Koch Modular (part of the Koch Industries) has been signed to also explore licensing for USA, Canada and Mexico. A non-binding agreement with ABE Gruppe GmbH and BKW AG has been signed to explore the deployment of 175MW of electrolysis capability from CPH2 across Switzerland and Germany. The Company has an engagement with Siemens, as part of a non-binding MoU to support technology development.
The new strategy will leverage existing and extensive IP to support a broader industrial client base with licensable tech and know-how. Revenue is expected to be generated through Technology Transfer Agreements via packaged sales of existing IP-based insight and capability.
Changes in Management
To lead this new strategy, the Board has resolved that Richard Scott, who was appointed to the role of Chief Commercial Officer in
Jonathan Duffy, Chief Executive Offer, and Christopher Train, Non-Executive Chair, have both offered their resignations to the Board and will step down from their roles. The Board changes will take effect following the completion of the Fundraise.
Reasons for Fundraising
The majority of the funds raised since IPO have been invested in engineering development, independent safety validation, supply‑chain development and manufacturing readiness, culminating in the commercial launch of the MFE220 unit and the progression of customer deployments.
The Company's working capital position remains constrained and CPH2 is undertaking a significant cost reduction programme. The expected cost base from
Directors Participation
Certain Directors of the Company have noted their intention to participate in the Fundraising via the Directors Subscription. This subscription is for an aggregate of 666,667 Directors Subscription Shares at the Issue Price. A further announcement will be made in due course regarding the Directors Subscription. Details of the intended participation in the Directors Subscription are set out below:
|
Name |
Title |
Number of existing Ordinary Shares |
Number of Directors Subscription Shares subscribed for |
Resulting shareholding following subscription |
|
James Hobson |
Chief Financial Officer |
161,666 |
333,334 |
495,000 |
|
Richard Scott |
Chief Executive Office Elect |
500,000 |
333.333 |
833,333 |
A separate announcement will be released in due course relating to the Directors Subscription once the Directors Subscription has been finalised.
Broker Warrants
Under the Placing Agreement, TPI will be issued with warrants equal to ten per cent. of the number of Ordinary Shares issued in connection with the Fundraising, entitling the holder to subscribe for one new Ordinary Share at the Issue Price for five years following Admission.
In addition, the Company has agreed with West Hill that West Hill will be issued with warrants equal to ten per cent. of the number of Ordinary Shares issued in connection with Subscription, entitling the holder to subscribe for one new Ordinary Share at the Issue Price for five years following Admission.
These broker warrants will be issued following the General Meeting and settlement of all shares to be issued in connection with the Fundraising. Broker warrants will only be issued in certificated form and will be freely transferable. No fractions of broker warrants will be issued. The broker warrants will not be listed on AIM or any other exchange.
It should be noted that if the Resolutions are not passed at the General Meeting the broker warrants will not be issued.
Current Trading
During 2025 the Company successfully raised gross proceeds of approximately
Audited results for the year ended
On
On
On
The CLN shall convert at a 46% discount to the price applicable to the relevant conversion event, subject to a gross pricing cap of
The
In addition to the CLN, CPH2 and Hidrigin have agreed to, within 28 days of the Term Sheet, enter into a nine month exclusivity agreement to negotiate and complete a Strategic Partnership and Manufacturing and Technology Development Agreement, with the opportunity for Hidrigin to serve as the exclusive manufacturing partner (via its engineering partner Jones Engineering) of CPH2 in the United Kingdom, Ireland, the United States, Canada and Mexico. Any design and manufacturing improvements relating to the IP are expected to be jointly owned by the Company and Hidrigin. The binding Term Sheet has a long stop date of
On
Use of proceeds from the Fundraising
The net proceeds from the Fundraising will be used to support the revised strategic direction with focus a focus on transitioning towards a capital-light model, centred on strategic partnerships, manufacturing agreements and the global licensing of its proprietary technology. The Board believes that the Company's membrane-free technology has demonstrated significant technical merit and that its existing IP holds significant commercial value.
Specifically, the net proceeds will be used to:
· Implement the revised capital-light business model, with monthly cash burn of
· Complete the investigation into the MFE220 test-site incident by
· Progress strategic initiatives, including manufacturing partnerships and the negotiation and execution of the Company's first Technology Transfer Agreement to generate revenues under the new strategy
· Provide general working capital to support the business over the next 12 months, expected to extend to
Shareholders should note that, in the event that the Fundraising does not proceed and alternative funding is not available on suitable terms or at all, the amount of working capital available to the Company will be severely limited. The current cash balance is sufficient for the Company to continue operating through to
The Company will shortly be posting a Notice of General Meeting and an accompanying circular (the "Circular") to existing shareholders following this announcement. All relevant documents will be available to download at: https://www.cph2.com/investors/circulars-documents/
Admission & Total Voting Rights
Application will be made to the London Stock Exchange for the Firm Placing Shares to be admitted to trading on AIM ("Admission"). It is expected that dealings in the Firm Placing Shares will commence on or around
Following Admission, the Company will have 671,346,416 Ordinary Shares in issue. For the avoidance of doubt, if the Placing Agreement between the Company, TPI and Cavendish is terminated prior to Admission then the Firm Placing will not occur. The Firm Placing Shares, when issued, will be credited as fully paid and will rank on Admission pari passu in all respects with each other and with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.
Suspension of Trading
With the announcement of this Fundraising and the anticipated publication of the Annual Report to follow shortly today under a separate announcement, the temporary suspension of trading in the ordinary shares of the Company is expected to be lifted on Admission.
For more information, please contact:
|
Clean Power Hydrogen plc |
+44 (0)130 232 8075 |
|
Richard Scott, Chief Executive Officer Elect |
|
|
James Hobson, Chief Financial Officer |
|
|
|
|
|
Cavendish Capital Markets Limited - NOMAD & Joint Broker |
|
|
Neil McDonald |
+44 (0)131 220 9771 |
|
Peter Lynch |
+44 (0)131 220 9772 |
|
Hanna Leijonmarck |
+44 (0)20 7908 6029 |
|
|
|
|
Turner Pope Investments (TPI) Ltd - Joint Broker |
|
|
Andy Thacker |
+44 (0)20 3657 0050 |
|
Guy McDougall |
|
Background on CPH2
CPH2 is the holding company of Clean Power Hydrogen Group Limited which has a decade of dedicated research and product development experience that has delivered global patents in breakthrough hydrogen and oxygen production technology. The Group's strategic objective is to deliver the lowest lifetime LCOH in the market in relation to the production of hydrogen for the growing electrolysis or decentralised markets and alternative energy markets. CPH2 is listed on the AIM market and trades under the ticker AIM:CPH2.
For more information: https://www.cph2.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE